Literature DB >> 17530289

A locus on chromosome 10 influences C-reactive protein levels in two independent populations.

Ulrich Broeckel1, Christian Hengstenberg, Bjoern Mayer, Karen Maresso, Daniel Gaudet, Ondrej Seda, Johanne Tremblay, Stephan Holmer, Jeanette Erdmann, Christian Glöckner, Michael Harrison, Lisa J Martin, Jeff T Williams, Gerd Schmitz, Guenter A J Riegger, Howard J Jacob, Pavel Hamet, Heribert Schunkert.   

Abstract

High sensitivity C-reactive protein (hsCRP) is an independent risk factor for cardiovascular disease, such as stroke or coronary artery disease. Genetic factors influence significantly the inter-individual variability of hsCRP. The aim of this study was to identify genomic regions influencing hsCRP levels. A genome scan was performed in two independent studies of Caucasian populations, namely 513 Western-European families ascertained for myocardial infarction (n = 1,406) and 120 French-Canadian families diagnosed with hypertension (n = 758). In the myocardial infarction families, 31% of the inter-individual variation of hsCRP levels was explained by genetic factors (P = 0.0000015) and loci influencing hsCRP were identified on chromosomes 10 (at 141 cM) and 5 (at 150 cM) with multipoint LOD scores of 3.15 and 2.23, respectively. An additional suggestive signal was detected on chromosome 2 in subset analyses. A similar degree of heritability has been observed in a second independent population of French-Canadian hypertensive families for hsCRP (30%) and linkage results for chromosome 10 were confirmed with maximum LOD score of 2.7. We identified a chromosomal region in two independent populations which influences hsCRP in addition to several unique regions. This provides targets for the identification of genes involved in the regulation of hsCRP and the development and progression of vascular disease, including stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530289     DOI: 10.1007/s00439-007-0380-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   5.881


  29 in total

1.  Need to test the arterial inflammation hypothesis.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

2.  Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension.

Authors:  P Hamet; E Merlo; O Seda; U Broeckel; J Tremblay; M Kaldunski; D Gaudet; G Bouchard; B Deslauriers; F Gagnon; G Antoniol; Z Pausová; M Labuda; M Jomphe; F Gossard; G Tremblay; R Kirova; P Tonellato; S N Orlov; J Pintos; J Platko; T J Hudson; J D Rioux; T A Kotchen; A W Cowley
Journal:  Am J Hum Genet       Date:  2005-03-30       Impact factor: 11.025

3.  C-reactive protein and its role in metabolic syndrome: mendelian randomisation study.

Authors:  Nicholas J Timpson; Debbie A Lawlor; Roger M Harbord; Tom R Gaunt; Ian N M Day; Lyle J Palmer; Andrew T Hattersley; Shah Ebrahim; Gordon D O Lowe; Ann Rumley; George Davey Smith
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

Review 4.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

5.  Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype.

Authors:  Claes Ladenvall; Katarina Jood; Christian Blomstrand; Staffan Nilsson; Christina Jern; Per Ladenvall
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

6.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

7.  C-reactive protein levels and outcomes after statin therapy.

Authors:  Paul M Ridker; Christopher P Cannon; David Morrow; Nader Rifai; Lynda M Rose; Carolyn H McCabe; Marc A Pfeffer; Eugene Braunwald
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

8.  Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein.

Authors:  Mark A Vickers; Fiona R Green; Catherine Terry; Bongani M Mayosi; Cecile Julier; Mark Lathrop; Peter J Ratcliffe; Hugh C Watkins; Bernard Keavney
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

9.  Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels.

Authors:  Christopher S Carlson; Shelley Force Aldred; Philip K Lee; Russell P Tracy; Stephen M Schwartz; Mark Rieder; Kiang Liu; O Dale Williams; Carlos Iribarren; E Cora Lewis; Myriam Fornage; Eric Boerwinkle; Myron Gross; Cashell Jaquish; Deborah A Nickerson; Richard M Myers; David S Siscovick; Alexander P Reiner
Journal:  Am J Hum Genet       Date:  2005-05-16       Impact factor: 11.025

10.  Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis.

Authors:  Robert Y L Zee; Paul M Ridker
Journal:  Atherosclerosis       Date:  2002-05       Impact factor: 5.162

View more
  3 in total

1.  Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.

Authors:  Alexander P Reiner; Mark M Wurfel; Leslie A Lange; Christopher S Carlson; Alex S Nord; Cara L Carty; Mark J Rieder; Cindy Desmarais; Nancy S Jenny; Carlos Iribarren; Jeremy D Walston; O Dale Williams; Deborah A Nickerson; Gail P Jarvik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

2.  "Big data" in economic history.

Authors:  Myron P Gutmann; Emily Klancher Merchant; Evan Roberts
Journal:  J Econ Hist       Date:  2018-04-03

3.  Genetic analysis of hsCRP in American Indians: The Strong Heart Family Study.

Authors:  Lyle G Best; Poojitha Balakrishnan; Shelley A Cole; Karin Haack; Jonathan M Kocarnik; Nathan Pankratz; Matthew Z Anderson; Nora Franceschini; Barbara V Howard; Elisa T Lee; Kari E North; Jason G Umans; Joseph M Yracheta; Ana Navas-Acien; V Saroja Voruganti
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.